Triple-Combo Single Pill for HIV Approved

Triumeq(R), the first-ever single pill triple drug combination against HIV, was approved absed on the results of 2 clinical trials.

ViiV Healthcare announced today that the US Food and Drug Administration (FDA) has approved Triumeq((R)) (abacavir 600mg, dolutegravir 50 mg and lamivudine 300mg) tablets for the treatment of HIV-1 infection.(1) Triumeq is ViiV Healthcare's first dolutegravir-based fixed-dose combination, offering many people living with HIV the option of a single-pill regimen that combines the integrase strand transfer inhibitor (INSTI) dolutegravir, with the nucleoside reverse transcriptase inhibitors (NRTIs) abacavir and lamivudine.

Triumeq alone is not recommended for use in patients with current or past history of resistance to any components of Triumeq. Triumeq alone is not recommended in patients with resistance-associated integrase substitutions or clinically suspected INSTI resistance because the dose of dolutegravir in Triumeq is insufficient in these populations. Before initiating treatment with abacavir-containing products, screening for the presence of a genetic marker, the HLA-B*5701 allele, should be performed in any HIV-infected patient, irrespective of racial origin. Products containing abacavir should not be used in patients known to carry the HLA-B*5701 allele.

Source: MarketWatch

Related Videos
Related Content
© 2023 MJH Life Sciences
All rights reserved.